GLP-1 Agonists in Type 1 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like peptide 1 (GLP-1) agonists, incretin, liraglutide, exenatide, albiglutide, dulaglutide, type 1 diabetes mellitus. Study Selection and Data Extraction: All English-language trials that examined glycemic end points using GLP-1 agonists in humans with T1DM were included. Data Synthesis: A total of 9 clinical trials examining the use of GLP-1 agonists in T1DM were identified. On average, hemoglobin A 1C (A1C) was lower than baseline, with a maximal lowering of 0.6%. This effect was not significant when tested against a control group, with a relative decrease in A1C of 0.1% to 0.2%. In all trials examined, reported hypoglycemia was low, demonstrating no difference when compared with insulin monotherapy. Weight loss was seen in all trials, with a maximum weight loss of 6.4 kg over 24 weeks. Gastrointestinal adverse effects are potentially limiting, with a significant number of patients in trials reporting nausea. Conclusion: The use of GLP-1 agonists should be considered in T1DM patients who are overweight or obese and not at glycemic goals despite aggressive insulin therapy; however, tolerability of these agents is a potential concern. Liraglutide has the strongest evidence for use and would be the agent of choice for use in overweight or obese adult patients with uncontrolled T1DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832 · cited 1×
“6 kg over a period of 10 years.(9) In addition, many patients fail to reach A1C goals despite aggressive treatment.”
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Temporal patterns in overweight and obesity in type 1 diabetes
Conway, B., Miller, R. G., Costacou, T., Fried, L., Kelsey, S., Evans, R. W., & Orchard, T. J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02956.x · Cited by 326 · cited 1×
“Owing to an increased prevalence of obesity in T1DM and its association with insulin resistance, innovative approaches to glucose control have become necessary.(4) An explosion of novel antidiabetic treatments have recently come into the market, but only pramlintide (Symlin), an analog of amylin, has gained Food and D…”
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235
Delgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235 · cited 2×
“Because GLP-1 activity is a glucose-dependent mechanism, risk for hypoglycemia is low.(19) Additionally, GLP-1 slows gastric emptying through effects on the autonomic nervous system and acts centrally to increase satiety.”
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103 · cited 1×
“Drop-out rates as a result of ADRs were similar across all trials, and the difference was not statistically significant when compared with placebo.(26,27) A recently published, double-blinded, randomized, placebo-controlled trial, the Lira-1 study, recruited 100 participants with uncontrolled T1DM (A1C > 8%) who were…”
Research works printed but not linked: 26
- 10.1056/NEJM199309303291401 · DOI · Paper page
- 10.1016/j.clim.2013.04.006 · DOI
- 10.2337/dc16-S005 · DOI · Paper page
- 10.2310/JIM.0b013e318279b7d6 · DOI · Paper page
- 10.1111/j.1463-1326.2006.00599.x · DOI
- 10.1371/journal.pone.0137525 · DOI · Paper page
- 10.1111/j.1464-5491.2011.03331.x · DOI · Paper page
- 10.1371/journal.pone.0141085 · DOI · Paper page
- 10.1177/0897190014549837 · DOI
- 10.1016/j.diabres.2013.01.020 · DOI
- 10.2337/dc09-1959 · DOI · Paper page
- 10.1007/s00592-015-0800-6 · DOI
- 10.1177/1932296814542153 · DOI · Paper page
- 10.2337/dc13-1169 · DOI · Paper page
- 10.1016/j.jcjd.2013.10.006 · DOI · Paper page
- 10.1016/S2213-8587(15)00436-2 · DOI · Paper page
- 10.2337/dc11-0096 · DOI · Paper page
- 10.1530/EJE-11-0330 · DOI · Paper page
- 10.4158/EP13065.OR · DOI
- Exenatide, 2016, Red Book Online [database online]
- Liraglutide, 2015, Red Book Online [database online]
- 10.1007/s40261-016-0389-8 · DOI
- 10.1111/dom.12386 · DOI · Paper page
- 10.1111/j.1365-2125.2008.03221.x · DOI · Paper page
- 10.2337/dc08-1309 · DOI · Paper page
- 10.2337/dc15-1025 · DOI · Paper page
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Weight management in patients with type 1 diabetes and obesity
Mottalib, A., Kasetty, M., Mar, J. Y., Elseaidy, T., Ashrafzadeh, S., & Hamdy, O. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0918-8 · Cited by 149
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Metadata
- Authors
- Janzen, K. M., Steuber, T. D., & Nisly, S. A.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2016-06-01
- Volume
- 50
- Issue
- 8
- Pages
- 656-665
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2418981277
- Cited by
- 53
- References
- 12
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 Agonists in Type 1 Diabetes Mellitus. https://app.cochat.ai/papers/10.1177/1060028016651279
- The paper
- Janzen, K. M., Steuber, T. D., & Nisly, S. A. (2016). GLP-1 Agonists in Type 1 Diabetes Mellitus. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028016651279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.